Exenatide use in the management of metabolic syndrome: A retrospective data base study

Endocrine Practice

Volumn 14, Issue 8, 2008, Pages 933-999

  Bhushan, Rajat ^a   Elkind Hirsch, Karen E ^a   Bhushan, Madhu ^a   Butler, William J ^a   Duncan, Kelly ^a   Marrioneaux, Ory ^a  

^a Metabolic Center of Louisiana Research Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; CHOLESTEROL; PEPTIDE; VENOM;

ADULT; AGED; ANTHROPOMETRIC PARAMETERS; ANTHROPOMETRY; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; ENDOCRINE DISEASE; FEMALE; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; RETROSPECTIVE STUDY; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; ADOLESCENT; BLOOD; BLOOD PRESSURE; METABOLISM; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; BLOOD PRESSURE; BODY MASS INDEX; BODY WEIGHT; CHOLESTEROL; CHOLESTEROL, HDL; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PEPTIDES; RETROSPECTIVE STUDIES; TRIGLYCERIDES; VENOMS; YOUNG ADULT;

EID: 65849411794     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/ep.14.8.993     Document Type: Article

References (38)

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
2. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med. 1989;149:1514-1520.
3. Björntorp P. Visceral obesity: "a civilization syndrome." Obes Res. 1993;1:206-222.
4. Björntorp P. Abdominal obesity and the metabolic syndrome. Ann Med. 1992;24:465-468.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
6. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-689.
7. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes. 1992;41: 715-722.
8. Lee CC, Kasa-Vubu JZ, Supiano MA. Androgenicity and obesity are independently associated with insulin sensitivity in postmenopausal women. Metabolism. 2004;53:507-512.
9. Landin K, Krotkiewski M, Smith U. Importance of obesity for the metabolic abnormalities associated with an abdominal fat distribution. Metabolism. 1989;38:572-576,
10. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
11. Tuomilehto J, Lindström J, Eriksson JG, et al; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344: 1343-1350.
12. Chiasson JL, Josse RG, Gomis R, et al; STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072-2077.
13. Knowler WC, Hamman RF, Edelstein SL, et al; Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes. 2005;54:1150-1156.
14. Grundy SM Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov. 2006;5:295-309.
15. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab. 2004;287: E199-E206.
16. Drucker DJ. Glucagon-like peptides. Diabetes. 1998;47: 159-169.
17. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003;26:2929-2940.
18. Raufman JP. Bioactive peptides from lizard venoms. Regul Pept. 1996;61:1-18.
19. Göke R, Fehmann HC, Linn T, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem. 1993; 268:19650-19655.
20. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004;117:77-88.
21. Fehse F, Trautmann M, Holst JJ, et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2005;90:5991-5997.
22. Poon T, Nelson P, Shen L, et al. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther. 2005;7:467-477.
23. Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm. 2005;62:173-181.
24. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87:1239-1246.
25. Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept. 2003;114:115-121.
26. Degn KB, Brock B, Juhl CB, et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes. 2004;53:2397-2403.
27. Schirra J, Sturm K, Leicht P, Arnold R, Göke B, Katschinski M. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J Clin Invest. 1998;101:1421-1430.
28. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092-1100.
29. Buse JB, Henry RR, Han J, et al; Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-2635.
30. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083-1091.
31. Edwards CM, Stanley SA, Davis R, et al Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab. 2001;281:155-161.
32. Kohen-Avramoglu R, Theriault A, Adeli K. Emergence of metabolic syndrome in childhood: An epidemiological overview and mechanistic link to dyslipidemia. Clin Biochem. 2003;36:413-420.
33. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006;8:436-447.
34. Buse JB, Klonoff DC, Nielsen LL, et al Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther. 2007;29:139-153.
35. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101:515-520.
36. Gutzwiller JP, Göke B, Drewe J, et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut. 1999;44:81-86.
37. Gutzwiller JP, Drewe J, Göke B, et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol. 1999;276: R1541-R1544.
38. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.